You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,119,129

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,119,129

Title:	Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
Abstract:	Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s):	Jure-Kunkel; Maria (Plainsboro, NJ), Lee; Francis Y. (Yardley, PA)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	12/462,168
Patent Claims:	1. A method for the treatment of cancer, consisting of the administration to a mammal in need thereof a synergistic, therapeutically effective amount of (i) an anti-CTLA-4 antibody, in addition to one or more diluents, vehicles, excipients, and/or inactive ingredients, and (ii) a chemotherapeutic agent, wherein said chemotherapeutic agent is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-me- thyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in addition to one or more diluents, vehicles, excipients, and/or inactive ingredients. 2. The method according to claim 1, wherein the anti-CTLA-4 antibody is selected from the group consisting of ipilimumab and tremelimumab. 3. The method according to claim 1, wherein said cancer is a solid tumor. 4. The method according to claim 3, wherein said solid tumor is selected from the group consisting of: lung cancer, pancreatic cancer, prostate cancer, and colon cancer. 5. The method according to claim 1, wherein said method is for the treatment of a tumor refractory to said chemotherapeutic agent. 6. The method according to claim 1, wherein said chemotherapeutic agent is administered concurrently with the administration of said anti-CTLA4 antibody. 7. The method according to claim 1, wherein said chemotherapeutic agent is administered before the administration of said anti-CTLA4 antibody. 8. The method according to claim 1, wherein said chemotherapeutic agent is administered essentially simultaneously with the administration of said anti-CTLA4 antibody. 9. The method according to claim 1, wherein said chemotherapeutic agent is administered daily. 10. The method according to claim 1, wherein said chemotherapeutic agent is administered intermittently for five days followed by two days without treatment. 11. The method according to claim 1, wherein said anti-CTLA4 antibody is administered about every three weeks.

Details for Patent 8,119,129

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011	⤷ Try a Trial	2028-08-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.